Figure 5
5-HT and TPH immunoreactivity in the DRN of MS rats treated with anti-nesfatin-1/NUCB-2 or vehicle. (A) Representative examples of sections processed for 5-HT or TPH immunostaining from MS rats microinjected with anti-nesfatin-1/NUCB-2 or vehicle into the DRN; A1: MS + anti-nesfatin-1/NUCB-2–5-HT; A2: MS + anti-nesfatin-1/NUCB-2–TPH; A3: MS + vehicle–5-HT; and A4: MS + vehicle–TPH. (B)Number of 5-HT-immunopositive cells in the DRN of anti-nesfatin-1/NUCB-2-or vehicle-microinjected MS rats. (C)Number of TPH-immunopositive cells in the DRN of anti-nesfatin-1/NUCB-2-or vehicle-microinjected MS rats. Anti-nesfatin-1/NUCB2 microinjection resulted in a significant reduction in the number of 5-HT-and TPH-immunopositive cells in the DRN of MS rats. [*p < 0.05, **p < 0.01] (n = 6 for each group).
